nice_老虎社区_美港股上老虎

38b9edcf
2021-07-22

nice

Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO

(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is consideri

Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":172021138,"tweetId":"172021138","gmtCreate":1626921880624,"gmtModify":1633769698776,"author":{"id":3583574689072529,"idStr":"3583574689072529","authorId":3583574689072529,"authorIdStr":"3583574689072529","name":"38b9edcf","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>nice</p></body></html>","htmlText":"<html><head></head><body><p>nice</p></body></html>","text":"nice","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/172021138","repostId":2153643390,"repostType":4,"repost":{"id":"2153643390","kind":"news","pubTimestamp":1626919402,"share":"https://ttm.financial/m/news/2153643390?lang=&edition=full","pubTime":"2021-07-22 10:03","market":"us","language":"en","title":"Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2153643390","media":"Bloomberg","summary":"(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is consideri","content":"<p>(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the matter.</p>\n<p>The company is interviewing investment banks as it weighs alternatives, which also include a private funding round, the people said, asking not to be identified because the matter is private.</p>\n<p>Hummingbird could seek to raise about $200 million to $300 million in a share sale, which could take place as soon as later this year, the people said. The company is leaning toward the U.S. as a preferred listing venue, they added.</p>\n<p>It plans to use part of the proceeds to support business expansion, the people said. No final decision has been made, the people said. Details such as the type of fundraising, size and timing could still change, they said.</p>\n<p>Hummingbird Bioscience is unable to comment on the speculation regarding an IPO, it said in an emailed statement in response to a Bloomberg News query. As a growth-stage biotech company, Hummingbird is continuously exploring future financing options, and remains focused on delivering against its development program and strategy, it said.</p>\n<p>The company focuses on developing treatments in areas such as oncology and autoimmunity in collaboration with global partners in academia and industry, according to its website.</p>\n<p>Hummingbird raised $125 million in a series C financing round in May led by Novo Holdings, the Danish private investor which is the controlling shareholder in Novo Nordisk A/S, the world’s largest maker of insulin. Other investors include Amgen Ventures, the venture capital arm of U.S. biotech giant Amgen Inc.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen-Backed Biotech Firm Hummingbird Weighing U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 10:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMGN":"安进"},"source_url":"https://finance.yahoo.com/news/amgen-backed-biotech-firm-hummingbird-101322071.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2153643390","content_text":"(Bloomberg) -- Hummingbird Bioscience, a Singaporean clinical-stage biotechnology firm, is considering fundraising options including an initial public offering, according to people familiar with the matter.\nThe company is interviewing investment banks as it weighs alternatives, which also include a private funding round, the people said, asking not to be identified because the matter is private.\nHummingbird could seek to raise about $200 million to $300 million in a share sale, which could take place as soon as later this year, the people said. The company is leaning toward the U.S. as a preferred listing venue, they added.\nIt plans to use part of the proceeds to support business expansion, the people said. No final decision has been made, the people said. Details such as the type of fundraising, size and timing could still change, they said.\nHummingbird Bioscience is unable to comment on the speculation regarding an IPO, it said in an emailed statement in response to a Bloomberg News query. As a growth-stage biotech company, Hummingbird is continuously exploring future financing options, and remains focused on delivering against its development program and strategy, it said.\nThe company focuses on developing treatments in areas such as oncology and autoimmunity in collaboration with global partners in academia and industry, according to its website.\nHummingbird raised $125 million in a series C financing round in May led by Novo Holdings, the Danish private investor which is the controlling shareholder in Novo Nordisk A/S, the world’s largest maker of insulin. Other investors include Amgen Ventures, the venture capital arm of U.S. biotech giant Amgen Inc.","news_type":1,"symbols_score_info":{"AMGN":0.9}},"isVote":1,"tweetType":1,"viewCount":482,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}